Copied


Vistra (VST) Stock Price Prediction: Analyst targets firm up as VST tests support after earnings and buyback update

Alvin Lang   Nov 18, 2026 15:19 0 Min Read


What changed

Vistra’s latest catalyst was the November 6 third-quarter 2026 results package, which showed GAAP net income of $1.14 billion and Ongoing Operations adjusted EBITDA of $2.378 billion, more than 50% above the prior-year quarter. Management also lifted the midpoint and narrowed 2026 guidance for adjusted EBITDA to $7.1 billion-$7.5 billion and adjusted FCFbG to $4.3 billion-$4.7 billion, then introduced 2027 ranges of $7.7 billion-$8.5 billion and $4.3 billion-$5.1 billion, respectively. The board also authorized another $1.5 billion of share repurchases, expected to be used by year-end 2028.

That backdrop matters because the stock is not trading as if the operational update has fully reset expectations. At $129.61, VST is still below the 7-day SMA at $131.04, the 20-day SMA at $130.77 and the 12-day EMA at $130.75, while the 50-day SMA sits much higher at $142.25. The near-term setup is therefore more about whether the market can hold the post-earnings base than about chasing momentum straight away.

Analyst pricing is constructive, but not uniform

Recent analyst work is still broadly supportive. BMO Capital maintained Outperform and raised its target to $196 from $188 on November 17, while Sanford C. Bernstein lifted its target to $182 from $181 and kept an Outperform rating. Scotiabank, however, cut its target to $169 from $189 on November 9, citing elevated political and headline risks in Texas while keeping Sector Outperform. Across the recent notes cited, targets span $169 to $198, with the higher end from Wells Fargo at $198 and the lower end from Scotiabank at $169.

MarketBeat also reported that Bernstein’s revised target implied 41.24% upside from the prior close and noted that consensus remains Moderate Buy with an average target of $200.86. That gives the name a favorable analyst backdrop, but the spread in targets shows there is still disagreement over how much of the improvement is already reflected in the shares.

Technical picture: recovering, but not yet confirmed

The chart is still working through a recovery phase rather than a clean breakout. VST’s daily RSI at 44.83 is neutral, not overbought, while MACD is negative at -3.1268 with a flat histogram, which points to fading downside momentum rather than strong upside confirmation. Stochastic %K at 72.40 versus %D at 57.92 suggests the stock has rebounded from weaker levels, but that move has not yet translated into a decisive trend reversal.

Price is sitting just above the pivot point at $129.98 and above immediate support at $126.35, with strong support at $123.10. Immediate resistance is $133.23, then $136.86. The Bollinger middle band at $130.77 is especially important here: VST is trading just beneath it, which makes that area the first real reclaim level. The broader moving average structure is described as an early bullish recovery, with MA7 above MA20, but the volume backdrop is light at 0.36x the 5-day average, so the bounce still needs confirmation from participation.

Derivatives positioning points to a bullish lean, not a clean signal

On Binance perpetual futures, funding is neutral at 0.0000%, open interest is 3,076.88 contracts, and open interest value stands at $407,166, up 1.10% over 24 hours. The long/short ratios lean to the long side: global accounts are 64.5% long and 35.5% short, while top-trader accounts are 68.1% long and 31.9% short. Taker flow is even more aggressive, with a 1-hour taker buy/sell ratio of 3.5247.

That mix suggests traders are leaning higher, but the neutral funding rate means the position buildup is not yet extreme. In practice, this is supportive only if spot price can hold above the nearby support cluster; if not, crowded long bias can unwind quickly.

Levels that matter next

The immediate battlefield is between $126.35 support and $133.23 resistance. A hold above the pivot at $129.98 and a recovery through the middle Bollinger band at $130.77 would keep the recovery intact and open a test of $133.23, then $136.86. Failure to hold $126.35 would expose $123.10, which is the cleaner invalidation level on the current structure.

The bigger-picture question is whether the post-earnings improvement in cash-flow and EBITDA guidance can pull the stock back toward the analyst target cluster. For now, the evidence supports a constructive but conditional setup: fundamentals and analyst revisions are helping, while the chart still needs confirmation.


Read More